News Astellas Pharma Inc. OTC Markets

Equities

ALPM.Y

US04623U1025

Market Closed - OTC Markets Other stock markets 03:59:59 2024-07-12 pm EDT			5-day change	1st Jan Change
10.46 ^USD	+1.26%		+4.39%	-12.10%

Jul. 02	Astellas Pharma Inc. Announces the Center for Drug Evaluation of the China National Medical Products Administration Approves Xtandi (Enzalutamide) for the Treatment of Patients with Metastatic Hormone-Sensitive Prostate Cancer	CI
Jun. 03	US FDA Acknowledges Astellas Pharma's Resubmission of Biologics License Application for Zolbetuximab	MT

Summary

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Astellas Pharma Inc. Announces the Center for Drug Evaluation of the China National Medical Products Administration Approves Xtandi (Enzalutamide) for the Treatment of Patients with Metastatic Hormone-Sensitive Prostate Cancer	Jul. 01	CI
US FDA Acknowledges Astellas Pharma's Resubmission of Biologics License Application for Zolbetuximab	Jun. 02	MT
U.S. Food and Drug Administration Acknowledges Astellas Pharma Inc.? Resubmission of Biologics License Application for Zolbetuximab and Sets New Action Date	May. 30	CI
Astellas Announces Collaboration with YASKAWA to Create an Innovative Cell Therapy Ecosystem through the Integration of Pharmaceutical and Robotics Technologies	May. 21	CI
Strong Cresemba(R) (isavuconazole) sales performance in Asia Pacific and China triggers milestone payment to Basilea	May. 16	DJ
Astellas Unveils New, State-Of-The-Art, $90 Million West Coast Innovation Center in the South San Francisco Biotech Corridor	May. 08	CI
Poseida Therapeutics to Receive Up to $600 Million in Cancer Gene Therapy Research, Development Deal With Xyphos	May. 02	MT
Malin Corp investee signs agreement with Astellas Pharma	May. 01	AN
Poseida Therapeutics Shares Rise 18% After Licensing Deal With Xyphos Biosciences	May. 01	DJ
Japan's Ono Pharma says $2.4 bln Deciphera purchase 'first step' for global expansion	Apr. 30	RE
Transcript : Astellas Pharma Inc., 2024 Earnings Call, Apr 25, 2024	Apr. 25
Astellas Pharma Inc. Declares Year End Dividend for the Year Ended March 31, 2023 and Provides Interim and Year End Dividend Guidance for the Fiscal Year 2024	Apr. 25	CI
Astellas Pharma Inc. Provides Consolidated Earnings Guidance on Full Basis for the Full-Year 2024	Apr. 25	CI
Astellas Pharma Inc. Reports Earnings Results for the Full Year Ended March 31, 2024	Apr. 25	CI
Astellas Pharma Inc. Announces Board and Committee Retirements	Apr. 25	CI
European Commission Approves Astellas Pharma Label Extension for Xtandi	Apr. 24	MT
Astellas Pharma Inc. Announces European Commission Approval for Use in Additional Recurrent Early Prostate Cancer Treatment Setting	Apr. 23	CI
Astellas Confirms Unfavorable District Court Decision Concerning its Motion for a Preliminary Injunction against Lupin and Zydus Generic Versions of MyrbetriqTM	Apr. 23	AQ
Takeda Teams Up With Astellas Pharma, Sumitomo Mitsui Banking to Support Incubation of Early Drug Discovery Programs	Apr. 22	MT
Takeda, Astellas and Sumitomo Mitsui Banking Announce Master Agreement to Establish Joint Venture Company for Incubation of Early Drug Discovery Programs	Apr. 22	CI

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

News Astellas Pharma Inc. OTC Markets

Equities

ALPM.Y

US04623U1025

Summary

Filters